<DOC>
	<DOC>NCT01900054</DOC>
	<brief_summary>The objective of this study is to evaluate the long-term safety and efficacy of TAU-284 (Bepotastine besilate) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.</brief_summary>
	<brief_title>A Long-Term Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis</brief_title>
	<detailed_description>This is a multicenter,open-label, single-arm, uncontrolled study to evaluate the safety and efficacy of TAU-284 (20 mg/day) in pediatric patients with perennial allergic rhinitis for 12 weeks administration.</detailed_description>
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<criteria>Patients aged between 7 and 15 years Patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic criteria Patients with a mean total score for the three major nasal symptoms [sneezing, rhinorrhea, and nasal congestion] of at least 3 on the basis of symptoms recorded in the nasal allergy diary during the observation period etc. Patients with vasomotor rhinitis or eosinophilic rhinitis Patients who have concurrent nasal disease that may affect the efficacy of TAU284 Patients with a history of any of the nasal surgical procedures Patients with current or previous history of drug allergy Patients who concurrently have renal function abnormalities that may cause safety problems etc.</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>TAU-284</keyword>
	<keyword>Bepotastine besilate</keyword>
	<keyword>Histamine H1 receptor antagonists</keyword>
	<keyword>children</keyword>
</DOC>